Administration of orlistat in a patient with familial hyperchylomicronemia

被引：13

作者：

Tzotzas, T

Krassas, GE

Bruckert, E

机构：

[1] Panagia Hosp, Dept Endocrinol & Metab, Thessaloniki 54622, Greece

[2] Hop Pitie, Serv Endocrinol Metab, AH HP, F-75651 Paris, France

来源：

ATHEROSCLEROSIS | 2002年 / 165卷 / 01期

关键词：

D O I：

10.1016/S0021-9150(02)00116-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：185 / 186

页数：2

共 8 条

[1] DETECTION AND CHARACTERIZATION OF THE HETEROZYGOTE STATE FOR LIPOPROTEIN-LIPASE DEFICIENCY [J].

BABIRAK, SP ;

IVERIUS, PH ;

FUJIMOTO, WY ;

BRUNZELL, JD .

ARTERIOSCLEROSIS, 1989, 9 (03) :326-334

[2]

Bhatnagar D, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P737

[3] The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study [J].

Muls, E ;

Kolanowski, J ;

Scheen, A ;

Van Gaal, L .

INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (11) :1713-1721

[4]

Nair D. R., 2000, International Journal of Obesity, V24, pS98

[5] RELATIONSHIP BETWEEN IMPROVED POSTPRANDIAL LIPEMIA AND LOW-DENSITY-LIPOPROTEIN METABOLISM DURING TREATMENT WITH TETRAHYDROLIPSTATIN, A PANCREATIC LIPASE INHIBITOR [J].

REITSMA, JB ;

CABEZAS, MC ;

DEBRUIN, TWA ;

ERKELENS, DW .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1994, 43 (03) :293-298

[6] Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk [J].

Ros, E .

ATHEROSCLEROSIS, 2000, 151 (02) :357-379

[7] Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers [J].

Shepard, TY ;

Jensen, DR ;

Blotner, S ;

Zhi, J ;

Guerciolini, R ;

Pace, D ;

Eckel, RH .

INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (02) :187-194

[8] Usefulness of orlistat in the treatment of severe hypertriglyceridemia [J].

Wierzbicki, AS ;

Reynolds, TM ;

Crook, MA .

AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) :229-+

← 1 →